依维莫司治疗原发灶不明的低分化神经内分泌癌：一例报告
Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report.
作者信息
Bou Zerdan Maroun, Hamouche Ramzi, Bouferraa Youssef, Chouairy Camil, Gholam Dany
机构信息
Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
Yale-Waterbury Internal Medicine Residency Program, Waterbury, CT, USA.
出版信息
SAGE Open Med Case Rep. 2022 Jun 24;10:2050313X221106987. doi: 10.1177/2050313X221106987. eCollection 2022.
Abstract
Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter's high toxicity profile new treatment options are being explored. In this case report, we describe a case of a patient with poorly differentiated neuroendocrine carcinoma of unknown primary treated with compassionate oral everolimus after his refusal of intravenous chemotherapy.
摘要
原发灶不明的恶性肿瘤在全部肿瘤中所占比例虽小但意义重大。神经内分泌癌是一种预后较差的罕见疾病，已知可表现为原发灶不明。治疗方法包括细胞毒性化疗，但鉴于后者毒性较高，人们正在探索新的治疗选择。在本病例报告中，我们描述了一例原发灶不明的低分化神经内分泌癌患者，在其拒绝静脉化疗后，接受了同情用药口服依维莫司治疗。
相似文献
1
Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report.
SAGE Open Med Case Rep. 2022 Jun 24;10:2050313X221106987. doi: 10.1177/2050313X221106987. eCollection 2022.
2
Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors.
Cancer Chemother Pharmacol. 2010 Apr;65(5):889-93. doi: 10.1007/s00280-009-1094-6. Epub 2009 Aug 6.
3
[Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].
Bull Cancer. 2016 Oct;103(10):880-895. doi: 10.1016/j.bulcan.2016.06.006. Epub 2016 Aug 6.
4
Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Chest. 2017 May;151(5):1141-1146. doi: 10.1016/j.chest.2016.06.018. Epub 2016 Jun 29.
5
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
BMC Cancer. 2019 Oct 16;19(1):960. doi: 10.1186/s12885-019-6214-z.
6
Compassionate use of everolimus in a patient with a neuroendocrine tumor: a case report and discussion of the literature.
Oncol Res. 2011;19(8-9):403-6. doi: 10.3727/096504011x13123323849799.
7
Multiple bilateral choroidal metastatic tumors from a small-cell neuroendocrine carcinoma of unknown primary site.
Eur J Ophthalmol. 2005 Jan-Feb;15(1):148-52. doi: 10.1177/112067210501500126.
8
PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Cancer Cytopathol. 2011 Jun 25;119(3):193-201. doi: 10.1002/cncy.20136. Epub 2011 Feb 15.
9
Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
World J Gastroenterol. 2016 Dec 7;22(45):9944-9953. doi: 10.3748/wjg.v22.i45.9944.
10
Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors.
Cancer Treat Rev. 2011 Aug;37(5):358-65. doi: 10.1016/j.ctrv.2011.03.002. Epub 2011 Apr 9.
引用本文的文献
1
Hypercalcemia and Bone Metastasis in a Case of Large Cell Neuroendocrine Carcinoma With Unknown Primary.
Case Rep Oncol Med. 2024 May 21;2024:8792291. doi: 10.1155/2024/8792291. eCollection 2024.
本文引用的文献
1
Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma.
Cureus. 2021 Jan 17;13(1):e12748. doi: 10.7759/cureus.12748.
2
The 2019 WHO classification of tumours of the digestive system.
Histopathology. 2020 Jan;76(2):182-188. doi: 10.1111/his.13975. Epub 2019 Nov 13.
3
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.
Drugs. 2019 Jan;79(1):21-42. doi: 10.1007/s40265-018-1033-0.
4
Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
Pancreas. 2017 Mar;46(3):302-305. doi: 10.1097/MPA.0000000000000762.
5
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas.
Oncology. 2017;92(3):170-172. doi: 10.1159/000452279. Epub 2016 Nov 12.
6
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17.
7
The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Am J Surg Pathol. 2015 May;39(5):683-90. doi: 10.1097/PAS.0000000000000408.
8
PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Cancer Lett. 2013 Jul 10;335(1):1-8. doi: 10.1016/j.canlet.2013.02.016. Epub 2013 Feb 16.
9
Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Neuroendocrinology. 2013;97(4):331-40. doi: 10.1159/000347063. Epub 2013 May 22.
10
mTOR signaling in growth control and disease.
Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017.
Zotero 插件